GPER Function in Breast Cancer: An Overview by Rosamaria Lappano et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MINI REVIEW ARTICLE
published: 06 May 2014
doi: 10.3389/fendo.2014.00066
GPER function in breast cancer: an overview
Rosamaria Lappano*, Assunta Pisano and Marcello Maggiolini
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy
Edited by:
Gabriella Castoria, Second University
of Naples, Italy
Reviewed by:
Ferdinando Auricchio, Second
University of Naples, Italy
Laura Corbo, Cancer Research Center
of Lyon, France
*Correspondence:
Rosamaria Lappano, Department of
Pharmacy, Health and Nutritional
Sciences, University of Calabria, Via P.
Bucci, Rende 87036, Italy
e-mail: lappanorosamaria@yahoo.it
The G-protein-coupled estrogen receptor-1 (GPER, formerly known as GPR30) has attracted
increasing interest, considering its ability to mediate estrogenic signaling in different cell
types, including the hormone-sensitive tumors like breast cancer. As observed for other
GPCR-mediated responses, the activation of the epidermal growth factor receptor is a fun-
damental integration point in the biological action triggered by GPER. A wide number of
natural and synthetic compounds, including estrogens and anti-estrogens, elicit stimulatory
effects in breast cancer through GPER up-regulation and activation, suggesting that GPER
function is associated with breast tumor progression and tamoxifen resistance. GPER has
also been proposed as a candidate biomarker in triple-negative breast cancer, opening a
novel scenario for a more comprehensive assessment of breast tumor patients.
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INTRODUCTION
Estrogen receptors (ERα and ERβ) belong to the family of ligand-
regulated transcription factors that mediate a wide range of
hormone-induced physiological responses (1). In addition, estro-
gen and their cognate receptors are mainly involved in the pro-
gression of hormone-sensitive tumors including breast cancer.
Consequently, selective estrogen receptor modulators (SERMs)
were developed and used for decades in order to suppress estrogen
signaling in patients with breast tumor. Tamoxifen, the first SERM
approved for the treatment of breast cancer, has evidenced the
ability to reduce both breast cancer recurrence and contra-lateral
cancer by approximately 40–50% in women with early breast can-
cer (2). Although tamoxifen has demonstrated the effectiveness
in preventing numerous ER-positive breast tumors, no benefi-
cial effects was observed in any of the clinical trials aimed to
evaluate the progression of ER-negative tumors (3). As several
long-term side-effects were associated with tamoxifen treatment,
including an increased risk of endometrial cancer and throm-
boembolism, additional SERMs like raloxifene were developed in
recent years. In this regard, clinical trials have demonstrated that
patients receiving raloxifene show a reduced amount of side-effects
than tamoxifen-treated women. Nevertheless, raloxifene exhib-
ited a fewer effectiveness than tamoxifen toward the prevention
of invasive breast cancer (3). More recently, a third-generation
SERM named lasofoxifene has evidenced high efficacy in reducing
the incidence of ER-positive breast cancer, along with decreased
side-effects compared to tamoxifen or raloxifene treatment (4).
However, the use of lasofoxifene has not yet been approved by
FDA in the prevention of breast cancer.
To date, an alternative strategy in preventing the progres-
sion of ER-dependent breast tumors is represented by drugs that
inhibit the aromatase enzyme and interfere with the biosynthesis
of estrogens, leading to a drastic reduction of circulating estrogen
levels (5). Accordingly, clinical trials have suggested that aromatase
inhibitors (AIs) are highly effective in preventing invasive ER-
positive breast tumors in high-risk women (6, 7), even though
significant side-effects have been observed in follow-up stud-
ies (8). The aforementioned observations indicate that SERMs
and AIs are not able to prevent the development of ER-negative
breast cancer, hence suggesting the need of additional prognos-
tic and predictive factors beyond ERα (9), toward more com-
prehensive therapeutic strategies particularly in these types of
tumors.
17β-Estradiol (E2) triggers rapid effects by activating numerous
transduction signaling, including the insulin-like growth factor I
receptor (IGF-IR) and members of the epidermal growth factor
receptor (EGFR) family (1, 10, 11). Moreover, it has been well
recognized the involvement of the G-protein-coupled receptor
named GPR30/GPER in rapid responses to both estrogens and
anti-estrogens (12). In this regard, it has been suggested that
these molecules can induce growth effects through the activa-
tion of GPER-mediated signaling in ER-negative breast tumors
(13–15). Taking also into account that one in four patients with
ER-positive tumors does not respond to anti-estrogens (16), the
existence of an alternative estrogen receptor as GPER, may pro-
vide the basis for a better understanding of novel mechanisms
by which estrogens/anti-estrogens stimulate the proliferation of
hormone-sensitive cancer cells, including breast carcinoma. Fur-
ther supporting these findings, the expression of GPER has been
found associated with the development of tamoxifen resistance in
breast cancer patients (17–19).
The numerous evidence that underline the complex action
exerted by GPER up-regulation and activation in the progression
of breast cancer will be summarized here, having also a look at the
chance to consider it as a further biological target for innovative
therapeutic strategies in breast tumor.
GPER SIGNALING IN BREAST CANCER CELLS
The initial studies, which elucidated some of the biological actions
exerted by GPER in breast cancer cells, like the activation of
rapid intracellular signaling induced by E2 and the ER antag-
onists tamoxifen and ICI 182, 780 (13, 14, 20), paved the way
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for a wide number of studies aimed to characterize the molecu-
lar mechanisms involved in GPER-mediated biological responses
like cancer cell growth, migration, and invasion. For instance, in
ER-negative breast cancer cells, the GPER-dependent ERK1/2 acti-
vation was shown to be consequent to the Gβγ subunit-dependent
transactivation of EGFR, which occurs through the cleavage and
the release of heparan-bound EGF (HB-EGF) by metallopro-
teinases (MMPs) (13). Likewise, the stimulation of adenylyl cyclase
and the cAMP-mediated inhibition of the EGFR/ERK pathway
was evidenced in rapid responses to estrogenic signals medi-
ated by GPER in ER-negative breast cancer cells (20). Besides,
GPER regulates a typical gene signature as also ascertained in a
microarray analysis (12, 15). Some of these GPER target genes are
involved in the progression of breast malignancies, like c-fos which
is induced by both estrogens and anti-estrogens in ER-negative
breast cancer cells through the involvement of the EGFR/MAPK
signaling cascade (14, 15, 21, 22). Other genes induced by estrogens
and anti-estrogens through the GPER-dependent pathway are the
early growth response-1 (Egr-1) (15, 23) and the connective tissue
growth factor (CTGF), which is also up-regulated by insulin-like
growth factor I (IGF-I) and hypoxia through GPER (15, 21, 22,
24, 25). Similar results were obtained in cancer-associated fibrob-
lasts (CAFs) derived from breast cancer samples, suggesting that
the stimulatory action of GPER may also be elicited through these
key players of the tumor microenvironment (15, 26–28). In accor-
dance with these findings, a recent study highlighted the potential
of GPER to mediate the production of estradiol in breast CAFs
through the activation of the EGFR/ERK signaling (29).
A variety of phyto- and xeno-estrogens are able to stimulate
rapid protein kinases activation, cAMP production, and gene tran-
scription in breast cancer cells through GPER, as observed upon
estrogen and anti-estrogen exposure (14, 30–35). In this regard,
it should be noted that many of the aforementioned compounds
exhibit binding properties for both the classical ER and GPER,
albeit some ligands exert opposite functions through these recep-
tors. For instance, estriol elicits ERα agonism but GPER antag-
onism in breast cancer cells (21), conversely OHT acts as ERα
antagonist and GPER agonist (12). Therefore, the identification
of selective GPER ligands is needed toward a better characteri-
zation of the GPER signaling along with the assessment of the
specific biological responses mediated by each estrogen receptor
subtype. So far, the selective GPER agonists G-1 (36), as well as
GPER-L1 and GPER-L2 (37), allowed the evaluation of the poten-
tial role played by GPER in breast cancer cells (21, 38, 39). In
addition, antagonist ligands of GPER were recently identified,
further contributing to a better understanding of GPER action
in different cell contexts (19, 22, 40–43). Among these GPER
antagonists, the compound named MIBE (22) showed the pecu-
liar property to inhibit both GPER- and ER-mediated signaling.
In this regard, it should be highlighted that a complex interplay
between GPER and ERα has been involved in gene expression
changes toward breast cancer progression (44, 45). Therefore,
MIBE could be used as an innovative pharmacological approach
in order to target breast carcinomas, which express one or both
receptors at the beginning and/or following tumor progression,
hence ensuring major therapeutic benefits with respect to the use
of ER antagonists.
GPER-MEDIATED BIOLOGICAL FUNCTIONS IN BREAST
CANCER CELLS
The ligand activation of GPER signaling along with the up-
regulation of certain GPER target genes were involved in the
proliferation of breast cancer cells, supporting the opinion that
GPER may contribute to breast carcinogenesis (21, 22, 30, 33, 38).
Likewise, it has been reported that GPER activation stimulates
the migration of breast cancer cells through CTGF (15), cyclin E
(43), the notch pathway (46), and the CXC receptor-1 (CXCR1)
(47). Furthermore, GPER agonists were shown to promote the
invasion of inflammatory breast cancer cells (48) as well as breast
cancer cell adhesion through the calcium-dependent cysteine pro-
tease (calpain) activation (49), suggesting a potential of GPER
to facilitate the progression of metastatic processes. Supporting
the potential involvement of GPER in breast cancer progression,
its activation lead to certain deformations of breast glandular
structure that characterize the malignant transformation of breast
tissue (50). Moreover, GPER-dependent proliferation of non-
tumorigenic breast epithelial cells was recently assessed, suggesting
a role for GPER also in estrogen-induced breast physiology and
pathology (51).
The proliferation and migration of breast cancer cells and CAFs
were also evidenced upon growth factor- and hypoxia-induced up-
regulation of GPER expression (24, 42, 52, 53). Of note, many of
these studies have revealed a cross-talk between EGFR and GPER
as observed for other GPCRs (25, 45, 52, 54–56). In particular, the
ligand activation of the EGFR transduction pathway was shown to
trigger GPER expression in both ER-negative and -positive breast
cancer cells (45, 54). Collectively, these findings suggested that this
mechanism may extend the potential of EGFR to engage estro-
genic signals in breast tumor progression. Analogously, EGFR was
involved in the up-regulation of GPER expression by hypoxia in
breast cancer cells and CAFs, indicating that GPER may also play
a role in hypoxia-induced angiogenesis (25, 52). Moreover, the
IGF-I was shown to be able to stimulate the expression of GPER
through the IGF-IR/PKC/MAPK transduction pathway in breast
cancer cells (24). Altogether, the ability of EGFR and IGF-IR lig-
ands as well as hypoxia to regulate GPER expression and function
may be included among the molecular mechanisms leading to
cell proliferation, migration, tumor angiogenesis that are mainly
involved in breast cancer progression.
GPER IN BREAST CARCINOMAS AND ITS ROLE IN THE
TAMOXIFEN RESISTANCE
G-protein-coupled estrogen receptor-1 is widely expressed in
breast cancer cell lines and breast primary tumors (13, 15, 54, 57,
58). By using an immunohistochemical-based approach in breast
carcinomas, Filardo and coworkers originally demonstrated that
the expression of GPER correlates with clinical and pathological
biomarkers of poor outcome as HER-2, increased tumor size and
metastasis (59). In patients with GPER-positive tumors treated
with tamoxifen, GPER expression results increased while the over-
all survival of patients decreased, contrary to what observed in
patients who did not receive tamoxifen (18). Likewise, it has been
recently reported that GPER overexpression and plasma mem-
brane (PM) localization represent crucial events in breast can-
cer progression as well as the absence of PM GPER was found
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associated with long-term prognosis in tamoxifen-treated pri-
mary breast cancer (60). On the basis of these data, it could be
argued that the treatment with tamoxifen in breast cancer patients
expressing high levels of GPER should be carefully evaluated.
A number of in vitro studies suggested that targeting GPER
signaling as well as interfering with the up-regulation of GPER
may be a potential strategy to hamper the resistance to tamoxifen-
based endocrine therapy in breast tumors. The initial evidence on
the ability of OHT to exert agonistic activity toward GPER in var-
ious cancer cell lines, including breast carcinoma (14, 34, 61, 62)
suggested that classical anti-estrogenic agents may stimulate rather
than inhibit a subset of tamoxifen-resistant tumors. In this regard,
it should be pointed out that in endometrial cancer cells, GPER
mediates biological responses not only to tamoxifen but also other
SERMs like raloxifene and the ER antagonist ICI 182,780 (63),
hence revealing an additional mechanism which may be involved
in the increased risk of endometrial cancer in patients treated with
these compounds. Moreover, EGFR ligands were shown to up-
regulate GPER expression by activating the EGFR/ERK transduc-
tion pathway in ER-positive tamoxifen-resistant breast cancer cells,
indicating that the activation of EGFR signaling may contribute to
tamoxifen resistance at least in part by up-regulating GPER expres-
sion (45). In accordance with these findings, estrogen stimulation
of tamoxifen-resistant breast cancer cells led to the up-regulation
of GPER, which in turn increased the cell sensitivity and responses
to GPER agonists (17). Further corroborating these data, the GPER
antagonist G-15 was recently shown to improve the response to
endocrine treatment in tamoxifen-resistant xenografts (19).
GPER IN TRIPLE-NEGATIVE BREAST CANCER CELLS
Approximately, 15–20% of all breast carcinomas are included in
the subgroup of triple-negative breast cancer (TNBC) that are
characterized by the lack of ERα, progesterone receptor (PR), and
EGFR 2 (Her-2) (64). TNBCs, which include diverse subtypes with
high levels of molecular heterogeneity, affect younger women and
display aggressive biological features, a higher rate of recurrence,
and a worse clinical outcome with respect to other breast cancer
types (8, 65, 66). As well-defined clinical targets are still lacking, the
standard chemotherapy remains the treatment option for women
with TNBC, even though promising agents are currently under
evaluation in prevention trials (8).
Recently, GPER has been evaluated as a candidate biomarker
and putative mechanism for growth regulation of TNBCs. In par-
ticular, the knockdown of GPER expression was shown to prevent
the proliferation of TNBC cells as well as the EGFR activation and
c-fos expression induced by E2 and OHT (67). Next, a potential
role elicited by GPER in TNBCs was suggested by a retrospective
analysis demonstrating that GPER is prevalent in TNBCs, associ-
ated with young age and possible malignant recurrence (68). Taken
together, these data suggest that the inhibition of GPER might be
an appropriate targeted therapy in TNBC; however, future studies
are needed to further corroborate the above-mentioned findings.
CONTROVERSIES AND CONCLUDING REMARKS
Controversies still exist on the localization of GPER and its func-
tion, in particular the potential action as pro-apoptotic mediator.
Although GPER belongs to a cell surface receptor family, which
conventionally mediates transmembrane signaling of membrane-
impermeable ligands, numerous studies demonstrated that GPER
is detectable at the PM or intracellular levels in breast cancer cells
(54, 58, 63, 69, 70). Interestingly, it was demonstrated that GPER
localizes within the nucleus of breast CAFs through a translo-
cation mechanism that is regulated in an importin-dependent
manner (26, 27). These findings are in line with other observations
regarding many GPCRs, which were detected into diverse cellular
compartments (71–73). Although further studies are required to
better understand the role played by GPCRs in relation to their
localization, the subcellular detection of GPER may be involved in
its downstream signaling activity. For instance, it has been recently
demonstrated that the different localization of GPER could reflect
distinct biological features of breast tumors (74). In particular,
cytoplasmic GPER was associated with non-ductal histologic sub-
types of breast cancer, low tumor stage, and better histologic
differentiation, whereas nuclear GPER was associated with poorly
differentiated carcinomas and triple-negative subtypes (74).
A further debate on GPER regards its potential action to inter-
fere with the progression of breast cancer. For instance, the phe-
nolic compounds contained in olive oil named oleuropein and
hydroxytyrosol, were recently identified as GPER inverse agonists
displaying the ability to inhibit the G-1-induced proliferation of
ER-negative breast cancer cells (75). A long-term ERK1/2 acti-
vation was proposed to explain at least in part the apoptotic
effects induced by oleuropein and hydroxytyrosol, although fur-
ther mechanisms should be taken into account as the GPER
silencing did not completely abrogate the action of oleuropein
on cell viability (75). Likewise, previous studies evidenced the
capability of G-1 to abolish the growth of breast cancer cells acti-
vating pro-apoptotic signals (39, 76–78). In this context, it should
be mentioned that in MDA-MB 231 breast cancer cells lacking
or minimally expressing GPER (13, 14, 57), the treatment with
2µM G-1 led to a suppression of cell growth, which persisted
also using the GPER antagonist G-15 (79). In accordance with
these findings, G-1 suppressed the proliferation of ovarian cancer
cells without the involvement of GPER, thus evidencing pro-
apoptotic properties that could be elicited in a GPER-independent
manner (80).
Further controversial observations have been reported on the
functional role exerted by GPER in the reproductive system, par-
ticularly in mouse models. For instance, GPER has been involved
in stimulating uterine epithelial proliferation in mice (40). How-
ever, GPER knockout mice did not displayed developmental or
functional defects in the reproductive organs (81, 82). Moreover,
G-1 treatment did not trigger proliferative responses in mammary
gland and endometrium in wild-type mice (82). Conversely, GPER
has been shown to regulate meiotic arrest in oocytes of the Atlantic
croaker and zebra fish (83, 84), the proliferative and apoptotic
pathways involved in spermatogenesis (44, 85, 86) during male
reproductive development, the estrogen-induced stimulation of
primordial follicle formation in the hamster ovary (87).
Despite the controversies regarding the role of GPER in breast
cancer, the in vitro and in vivo data available as well as the epidemi-
ological studies have ascertained that GPER may act as an estro-
gen receptor in different pathophysiological responses, including
breast cancer. GPER regulation and functions have also been
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involved in the resistance to tamoxifen in breast tumor patients,
thus therapeutic approaches targeting the GPER-mediated signal-
ing may be taken into account in setting innovative pharmacolog-
ical strategies, in particular to hamper the failure of classical anti-
estrogens in breast malignancy. The identification of further mol-
ecules targeting both estrogen receptor types is strongly required
to effectively reduce breast cancer incidence and recurrence.
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